Try our Advanced Search for more refined results
April 12, 2021
IN RE: Belviq (Lorcaserin HCI) Products Liability Litigation
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
August 10, 2021
No MDL For Weight Loss Carcinogen Cases, JPML Says
The Judicial Panel on Multidistrict Litigation on Tuesday refused to consolidate lawsuits alleging Eisai Inc. and Arena Pharmaceuticals Inc.'s weight loss drug Belviq causes cancer, saying too few suits have been filed since the drug was recalled.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login